Advertisement

Inflammation

, Volume 38, Issue 4, pp 1556–1562 | Cite as

Embelin Reduces Systemic Inflammation and Ameliorates Organ Injuries in Septic Rats Through Downregulating STAT3 and NF-κB Pathways

  • Xian-Long Zhou
  • Lei HuangEmail author
  • Jun Cao
Article

Abstract

Current evidence shows that the majority of the damage induced during sepsis is pursuant to induction and overproduction of endogenous cytokines. Embelin has been reported to suppress cytokine expressions in inflammatory disorders. The present study was designed to investigate the effects of embelin on cecal and ligation and puncture (CLP)-induced rat sepsis. Single-dose administration of embelin 1 h after surgery significantly improved survival of rats with CLP-induced sepsis. In addition, embelin treatment reduced the serum levels of pro-inflammatory cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 and decreased organ inflammation and injuries. Moreover, embelin suppressed the activation of p65 subunit of nuclear factor-kappa B (NF-κB) and signal transducers and activators of transcription 3 (STAT3). Collectively, these results indicated that embelin ameliorates sepsis in rats through suppressing STAT3 and NF-κB pathways.

KEY WORDS

sepsis embelin STAT3 NF-κB 

Notes

ACKNOWLEDGMENTS

We would like to thank the Center for Animal Experiment of Wuhan University (Wuhan, Hubei, China) for the assistance in animal experiment.

Conflict of Interest

None.

REFERENCES

  1. 1.
    Ortíz, G., C. Dueñas, F. Rodríguez, et al. 2014. Epidemiology of sepsis in Colombian intensive care units. Biomédica 34: 40–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Levy, M.M., M.P. Fink, J.C. Marshall, et al. 2001. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine 2003(31): 1250–1256.Google Scholar
  3. 3.
    Hotchkiss, R.S., and I.E. Karl. 2003. The pathophysiology and treatment of sepsis. New England Journal of Medicine 348: 138.PubMedCrossRefGoogle Scholar
  4. 4.
    Hack, C.E., L.A. Aarden, and L.G. Thijs. 1997. Role of cytokines in sepsis. Advances in Immunology 66: 95–101.Google Scholar
  5. 5.
    Lally, K.P., E. Cruz, and H. Xue. 2000. The role of anti-tumor necrosis factor-α and interleukin-10 in protecting murine neonates from Escherichia coli sepsis. Journal of Pediatric Surgery 35: 852–854. discussion 855.PubMedCrossRefGoogle Scholar
  6. 6.
    Panacek, E.A., J.C. Marshall, T.E. Albertson, et al. 2004. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Critical Care Medicine 32: 2173–2182.PubMedGoogle Scholar
  7. 7.
    Işeri, S.O., G. Sener, B. Saglam, et al. 2005. Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils. Journal of Surgical Research 126: 73–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Neviere, R.R., G. Cepinskas, W.S. Madorin, et al. 1999. LPS pretreatment ameliorates peritonitis-induced myocardial inflammation and dysfunction: role of myocytes. American Journal of Physiology 277: H885–H892.PubMedGoogle Scholar
  9. 9.
    Brown, K.A., S.D. Brain, J.D. Pearson, et al. 2006. Neutrophils in development of multiple organ failure in sepsis. Lancet 368: 157–169.PubMedCrossRefGoogle Scholar
  10. 10.
    Joshi, R., J.P. Kamat, and T. Mukherjee. 2007. Free radical scavenging reactions and antioxidant activity of embelin: biochemical and pulse radiolytic studies. Chemico-Biological Interactions 167: 125–134.PubMedCrossRefGoogle Scholar
  11. 11.
    Chitra, M., S. Devi, and E. Sukumar. 2003. Antibacterial activity of embelin. Fitoterapia 74: 401–403.PubMedCrossRefGoogle Scholar
  12. 12.
    Chitra, M., E. Sukumar, V. Suja, et al. 1994. Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy 40: 109–113.PubMedCrossRefGoogle Scholar
  13. 13.
    Kalyan Kumar, G., R. Dhamotharan, N.M. Kulkarni, et al. 2011. Embelin reduces cutaneous TNF-α level and ameliorates skin edema in acute and chronic model of skin inflammation in rats. European Journal of Pharmacology 662: 63–69.PubMedCrossRefGoogle Scholar
  14. 14.
    Kumar, G.K., R. Dhamotharan, N.M. Kulkarni, et al. 2011. Embelin ameliorates dextran sodium sulfate-induced colitis in rats. International Immunopharmacology 11: 724–731.CrossRefGoogle Scholar
  15. 15.
    Ahn, K.S., G. Sethi, and B.B. Aggarwal. 2007. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-κB (NF-κB) signaling pathway leading to suppression of NF-κB-regulated antiapoptotic and metastatic gene products. Molecular Pharmacology 71: 209–219.PubMedCrossRefGoogle Scholar
  16. 16.
    Heo, J.Y., H.J. Kim, S.M. Kim, et al. 2011. Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN. Cancer Letters 308: 71–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Abraham, E. 2003. Nuclear factor-kB and its role in sepsis-associated organ failure. Journal of Infectious Diseases 187(Suppl 2): S364–S369.PubMedCrossRefGoogle Scholar
  18. 18.
    Yu, Z., W. Zhang, and B.C. Kone. 2002. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochemical Journal 367: 97–105.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Williams, D.L., T. Ha, C. Li, et al. 1999. Early activation of hepatic NFkappaB and NF-IL6 in polymicrobial sepsis correlates with bacteremia, cytokine expression, and mortality. Annals of Surgery 230: 95–104.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Hillegass, L.M., D.E. Griswold, B. Brickson, et al. 1990. Assessment of myeloperoxidase activity in whole rat kidney. Journal of Pharmacological Methods 24: 285–295.PubMedCrossRefGoogle Scholar
  21. 21.
    Rittirsch, D., M.S. Huber-Lang, M.A. Flierl, et al. 2009. Immunodesign of experimental sepsis by cecal ligation and puncture. Nature Protocols 4: 31–36.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Sagy, M., Y. Al-Qaqaa, and P. Kim. 2013. Definitions and pathophysiology of sepsis. Current Problems in Pediatric and Adolescent Health Care 43: 260–263.PubMedCrossRefGoogle Scholar
  23. 23.
    Gong, X., L. Zhang, R. Jiang, et al. 2013. Anti-inflammatory effects of mangiferin on sepsis-induced lung injury in rats via up-regulation of heme oxygenase-1. Journal of Nutritional Biochemistry 24: 1173–1181.PubMedCrossRefGoogle Scholar
  24. 24.
    Zou, Y., T. Tao, Y. Tian, et al. 2013. Ginsenoside Rg1 improves survival in a murine model of polymicrobial sepsis by suppressing the inflammatory response and apoptosis of lymphocytes. Journal of Surgical Research 183: 760–766.PubMedCrossRefGoogle Scholar
  25. 25.
    Albayrak, A., Z. Halici, B. Polat, et al. 2013. Protective effects of lithium: a new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis. International Immunopharmacology 16: 35–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Baldwin Jr., A.S. 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annual Review of Immunology 14: 649–683.PubMedCrossRefGoogle Scholar
  27. 27.
    Liu, S.F., and A.B.. Malik. 2006. NF-κB activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology 290: L622–L645.Google Scholar
  28. 28.
    Brown, M.A., and W.K. Jones. 2004. NF-kappaB action in sepsis: the innate immune system and the heart. Frontiers in Bioscience 9: 1201–1217.PubMedCrossRefGoogle Scholar
  29. 29.
    Ang, S.F., S.M. Moochhala, P.A. MacAry, et al. 2011. Hydrogen sulfide and neurogenic inflammation in polymicrobial sepsis: involvement of substance P and ERK-NF-kB signaling. PLoS ONE 6: e24535.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Zhang, Y., Li, R., Zhu, J., et al. 2014. Etomidate increases mortality in septic rats through inhibition of nuclear factor kappa-B rather than by causing adrenal insufficiency. J Surg Res.Google Scholar
  31. 31.
    Riley, J.K., K. Takeda, S. Akira, et al. 1999. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory. Journal of Biological Chemistry 274: 16513–16521.PubMedCrossRefGoogle Scholar
  32. 32.
    Matsukawa, A., K. Takeda, S. Kudo, et al. 2003. Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils. Journal of Immunology 171: 6198–6205.CrossRefGoogle Scholar
  33. 33.
    Peña, G., B. Cai, J. Liu, et al. 2010. Unphosphorylated STAT3 modulates alpha7 nicotinic receptor signaling and cytokine production in sepsis. European Journal of Immunology 40: 2580–2589.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Guo, W., W. Liu, G. Chen, et al. 2012. Water-soluble andrographolide sulfonate exerts anti-sepsis action in mice through down-regulating p38 MAPK, STAT3 and NF-κB pathways. International Immunopharmacology 14: 613–619.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Emergency CenterZhongnan Hospital of Wuhan UniversityWuhanChina
  2. 2.Department of Burn & Plastic SurgeryZhongnan Hospital of Wuhan UniversityWuhanChina
  3. 3.Department of General SurgeryZhongnan Hospital of Wuhan UniversityWuhanChina

Personalised recommendations